PSMD10 (proteasome 26S subunit, non-ATPase 10), also known as Gankyrin, is a proteasomal chaperone that functions as an oncoprotein with complex roles in cancer development. PSMD10 suppresses apoptosis and promotes cell survival through multiple mechanisms. It negatively regulates tumor suppressors RB1 and p53 by facilitating their ubiquitination and proteasomal degradation 1. PSMD10 also regulates NF-κB signaling by promoting phosphorylation and transcriptional activation of RELA, leading to upregulation of anti-apoptotic genes including A20, cIAP1, cIAP2, and XIAP 1. Additionally, PSMD10 transcriptionally regulates β-catenin and RB1 to prevent TNF-α-induced cell death 1. PSMD10 overexpression is associated with poor prognosis in multiple cancers including hepatocellular carcinoma, cholangiocarcinoma, prostate cancer, and multiple myeloma 234. In cholangiocarcinoma, the MALAT1-miR-188-5p-PSMD10 regulatory axis promotes cell invasion and migration while suppressing apoptosis 3. PSMD10 knockdown sensitizes cancer cells to apoptosis and impairs tumor growth 25. Therapeutically, doxorubicin has been identified as a first-generation small molecule inhibitor targeting PSMD10 6, offering potential for cancer treatment strategies.